Search Results - "Miller, Kena C."

Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study by CHANAN-KHAN, Asher, MILLER, Kena C, SPANER, David, MOHR, Alice, BYRNE, Catriona, HERNANDEZ-ILIZALITURRI, Francisco, CHRYSTAL, Cynthia, STAROSTIK, Petr, CZUCZMAN, Myron S, MUSIAL, Laurie, LAWRENCE, David, PADMANABHAN, Swaminathan, TAKESHITA, Kenichi, PORTER, Carl W, GOODRICH, David W, BERNSTEIN, Zale P, WALLACE, Paul

“…Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) have profound immune defects and limited treatment options. Given the dramatic activity…”
Get full text

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response by Chanan‐Khan, Asher, Miller, Kena C., Lawrence, David, Padmanabhan, Swaminathan, Miller, Austin, Hernandez‐Illatazurri, Francisco, Czuczman, Myron S., Wallace, Paul K., Zeldis, Jerome B., Lee, Kelvin

“…BACKGROUND: In patients with chronic lymphocytic leukemia (CLL), treatment with lenalidomide induces a unique, previously uncharacterized, immune response…”
Get full text

Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1 by Chitta, Kasyapa S., Paulus, Aneel, Ailawadhi, Sikander, Foster, Barbara A., Moser, Michael T., Starostik, Petr, Masood, Aisha, Sher, Taimur, Miller, Kena C., Iancu, Dan M., Conroy, Jeffrey, Nowak, Norma J., Sait, Sheila N., Personett, David A., Coleman, Morton, Furman, Richard R., Martin, Peter, Ansell, Stephen M., Lee, Kelvin, Chanan-Khan, Asher A.

“…Abstract Understanding the biology of Waldenström macroglobulinemia is hindered by a lack of preclinical models. We report a novel cell line, RPCI-WM1, from a…”
Get full text

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study by Chanan-Khan, Asher A., Kaufman, Jonathan L., Mehta, Jayesh, Richardson, Paul G., Miller, Kena C., Lonial, Sagar, Munshi, Nikhil C., Schlossman, Robert, Tariman, Joseph, Singhal, Seema

“…Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes…”
Get full text

Plasma cell leukaemia and other aggressive plasma cell malignancies by Sher, Taimur, Miller, Kena C., Deeb, George, Lee, Kelvin, Chanan‐Khan, Asher

“…Summary Extramedullary plasma cell cancers, such as plasma cell leukaemia (PCL) and multiple extramedullary plasmacytomas (MEP) are very aggressive…”
Get full text

AT‐101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia by Paulus, Aneel, Chitta, Kasyapa, Akhtar, Sharoon, Personett, David, Miller, Kena C., Thompson, Kevin J., Carr, Jennifer, Kumar, Shaji, Roy, Vivek, Ansell, Stephen M., Mikhael, Joseph R., Dispenzieri, Angela, Reeder, Craig B., Rivera, Candido E., Foran, James, Chanan‐Khan, Asher

“…Summary Multiple myeloma, the second most common haematological malignancy in the U.S., is currently incurable. Disruption of the intrinsic apoptotic pathway…”
Get full text

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics by Sher, Taimur, Miller, Kena C., Lawrence, David, Whitworth, Amy, Hernandez-Ilizaliturri, Francisco, Czuczman, Myron S., Miller, Austin, Lawrence, William, Bilgrami, Syed Ali, Sood, Raman, Wood, Margaret T., Block, Annemarie W., Lee, Kelvin, Chanan-Khan, Asher Alban

“…Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their…”
Get full text

Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner by Masood, Aisha, Chitta, Kasyapa, Paulus, Aneel, Khan, A. Nazmul H., Sher, Taimur, Ersing, Noreen, Miller, Kena C., Manfredi, Deborah, Ailawadhi, Sikander, Borrelo, Ivan, Lee, Kelvin P., Chanan-Khan, Asher

“…Summary Over‐expression of anti‐apoptotic BCL2 has been reported in chronic lymphocytic leukaemia (CLL), but targeting BCL2 alone did not yield appreciable…”
Get full text

The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs by Paulus, Aneel, Masood, Aisha, Miller, Kena C., Nazmul H. Khan, A. N. M., Akhtar, Drusilla, Advani, Pooja, Foran, James, Rivera, Candido, Roy, Vivek, Colon‐Otero, Gerardo, Chitta, Kasyapa, Chanan‐Khan, Asher

“…Summary Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in the U.S. The course of the disease has been shown to be negatively…”
Get full text

Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells by Chitta, Kasyapa S., Khan, A. Nazmul H., Ersing, Noreen, Swaika, Abhisek, Masood, Aisha, Paulus, Aneel, Qadeer, Abdul, Advani, Pooja, Sher, Taimur, Miller, Kena C., Lee, Kelvin, Chanan-Khan, Asher A.

“…Abstract Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and is currently incurable. To expand the therapeutic armamentarium, we…”
Get full text

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL) by Chanan-Khan, Asher, Miller, Kena C., Takeshita, Kenichi, Koryzna, Alexandra, Donohue, Kathleen, Bernstein, Zale P., Mohr, Alice, Klippenstein, Donald, Wallace, Paul, Zeldis, Jerome B., Berger, Christine, Czuczman, Myron S.

“…Tumor necrosis factor α (TNF-α) and vascular endothelial growth factor (VEGF) play an important role in the biology of chronic lymphocytic leukemia (CLL)…”
Get full text

Clinical relapse in a patient with multiple myeloma presenting as an atrial plasmacytoma by Paulus, Aneel, Swaika, Abhisek, Miller, Kena C, Spangenthal, Edward J, Guo, Rongjun, Vonfricken, Kurt, Lee, Kelvin, Chanan-Khan, Asher A

Get full text

Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients by Swaika, Abhisek, Paulus, Aneel, Miller, Kena C, Sher, Taimur, Almyroudis, Nikolaos G, Ball, Donna, Wood, Margaret, Masood, Aisha, Lee, Kelvin, Chanan-Khan, Asher A

“…Previous studies have indicated that, in patients with multiple myeloma (MM), bortezomib is associated with an increased incidence of herpes zoster, resulting…”
Get more information

A steroid‐independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients by Sher, Taimur, Ailawadhi, Sikander, Miller, Kena C., Manfredi, Debbie, Wood, Margaret, Tan, Wei, Wilding, Gregory, Czuczman, Myron S., Hernandez‐Ilizaliturri, Francisco J., Hong, Fredrick, Sood, Raman, Soniwala, Saif, Lawrence, William, Jamshed, Saad, Masood, Aisha, Iancu, Daniel, Lee, Kelvin, Chanan‐Khan, Asher

“…Summary Novel agents have provided a new foundation for multiple myeloma therapies. When combined with other anti‐myeloma agents, these compounds significantly…”
Get full text

Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma by Ailawadhi, Sikander, Abdelhalim, Ahmed N., Derby, Lyudmyla, Mashtare, Terry L., Miller, Kena C., Wilding, Gregory E., Alberico, Ronald A., Gottlieb, Ronald, Klippenstein, Donald L., Lee, Kelvin, Chanan‐Khan, Asher A.

“…BACKGROUND: Multiple myeloma (MM) remains an incurable cancer. Treatment often is initiated at the time patients experience a progressive increase in tumor…”
Get full text

Monoallelic and Biallelic Deletions of 13q14.3 in Chronic Lymphocytic Leukemia: FISH vs miRNA RT-qPCR Detection by SMONSKEY, Matthew T, BLOCK, Annemarie W, DEEB, George, CHANAN-KHAN, Asher A, BERNSTEIN, Zale P, MILLER, Kena C, WALLACE, Paul K, STAROSTIK, Petr

“…Deletion of 13q14.3 (del(13q)) is the most common cytogenetic abnormality in chronic lymphocytic leukemia (CLL) and implies a favorable prognosis. We explored…”
Get full text

Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma by Manochakian, Rami, Miller, Kena C., Chanan‐Khan, Asher A.

“…Learning Objectives After completing this course, the reader will be able to: Discuss the efficacy of bortezomib as part of primary therapy for patients with…”
Get full text

Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis by Baz, Rachid, Patel, Mehul, Finley-Oliver, Elizabeth, Lebovic, Daniel, Hussein, Mohamad A., Miller, Kena C., Wood, Margaret, Sher, Taimur, Lee, Kelvin, Chanan-Khan, Asher A.

“…Recently, lenalidomide and low dose dexamethasone were found to result in superior overall survival compared to lenalidomide and high dose dexamethasone. The…”
Get full text

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial by Chanan-Khan, Asher, Miller, Kena C., Musial, Laurie, Padmanabhan, Swaminathan, Yu, Jihnhee, Ailawadhi, Sikander, Sher, Taimur, Mohr, Alice, Bernstein, Zale P., Barcos, Maurice, Patel, Mehul, Iancu, Dan, Lee, Kelvin, Czuczman, Myron S.

“…Novel agents have demonstrated enhanced efficacy when combined with other antimyeloma agents especially dexamethasone. The steroid doses employed in myeloma…”
Get full text

Management of patients with chronic lymphocytic leukemia treated with lenalidomide by Miller, Kena C, Musial, Laurie, Whitworth, Amy, Chanan-Khan, Asher

“…Lenalidomide is an immunomodulatory drug that has shown preliminary activity in the treatment of chronic lymphocytic leukemia (CLL). Much is known about the…”
Get full text